3 High Volume Biotech Penny Stocks to Watch Right Now
Over the past year and a half, biotech penny stocks have seen higher volume than average. This is the result of many factors in combination with one another. However, the largest impacting factor on biotech penny stocks during that time was and is Covid. While this initially began as a focus on Covid-related biotech stocks, it quickly evolved into a larger market focus.
And now, investors are enthused with the idea of finding the next big biotech penny stock to buy. Today, the biotech industry got another boost on news of both Moderna Inc.’s (NASDAQ: MRNA) HIV vaccine and the approval of booster shots by the FDA. This impacted stocks such as Pfizer Inc. (NYSE: PFE), and Johnson & Johnson (NYSE: JNJ).
It’s worth noting that biotech penny stocks can be highly volatile. But, finding high-volume stocks in the biotech sector can also be a profitable endeavor if done correctly and with the right research. Right now, there is a lot of momentum in the market in combination with a sizable degree of uncertainty around the future. So, taking all of this into consideration, let’s look at three biotech penny stocks to watch with high volume right now.
3 High Volume Biotech Penny Stocks to Watch
- Atossa Therapeutics Inc. (NASDAQ: ATOS)
- Evofem Biosciences Inc. (NASDAQ: EVFM)
- ReShape Lifesciences Inc. (NASDAQ: RSLS)
Atossa Therapeutics Inc. (NASDAQ: ATOS)
Atossa Therapeutics Inc. is a biotech company that creates medicines for infectious diseases and oncology purposes. Its main product is Endoxifen, which is in Phase 2 clinical trials to treat and prevent breast cancer. The company is also developing both AT-301 and AT-H201 for COVID-19 patients. YTD, shares of ATOS stock have increased by a staggering 250%. This is a reflection of its work on Covid, as well as its other prominent compounds.
On August 13th, the company announced its second-quarter results for 2021. The company received final data from its Phase 2 clinical study of oral Endoxifen during this period. Atossa also received authorization from Australian regulators to start a clinical study of AT-H201 for COVID-19. This is a big deal, especially considering the large uptick in cases as a result of the Delta variant.
“We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19.”President and CEO of Atossa, Dr. Steven Quay
Shortly after this announcement was made, shares of ATOS stock pushed up substantially. Considering this, will ATOS stock be on your list of penny stocks to watch?
Evofem Biosciences Inc. (NASDAQ: EVFM)
While shares of EVFM stock have not had the best few months, recent bullish trading could indicate that this may be turning around. For some context, Evofem is a biotech company that develops and commercializes products targeted at women’s sexual and reproductive health.
Its main commercialized product is Phexxi, which is a contraceptive gel for sale in many markets around the world. Additionally, Evofem has several anti-STD developments in the works, such as EVO100 which is an antimicrobial gel for preventing urogenital transmission of Chlamydia.
On August 11th, Evofem Biosciences released its second-quarter financial results for 2021. The company’s net product sales increased 68% quarter over quarter, which is a huge landmark for the company. In addition, the company reported an increase in Phexxi prescriptions, dispensed units, and its Phexxi prescriber base at 47%, 65%, and 52% increases respectively.
These are big numbers and show that the commercial adoption of Phexxi is continuing to increase. While gaining approval for a drug is one thing, getting it widely commercialized is a whole other ball game. For this reason, many investors are watching EVFM stock right now.
“We are pleased to show strong and sustainable growth in Phexxi prescriptions and dispensed units in the second quarter. This momentum allows us to further accelerate the growth trajectory with our celebrity campaign launching in early September.”The CEO of Evofem, Saundra Pelletier
With this new information in mind, will EVFM stock be on your watchlist in August 2021?
ReShape Lifesciences Inc. (NASDAQ: RSLS)
Another biotech company that could be worth watching this month is ReShape Lifesciences. This company is a weight loss and metabolic health solutions company that was founded in 2002. It has a well-integrated portfolio consisting of tested products and services to treat obesity and metabolic disease. Its Lap-Band Program has proven itself to be minimally invasive and successful for the long-term treatment of obesity. This is an alternative to much more invasive surgeries such as stapling procedures, gastric bypass, and sleeve gastrectomy.
Recently RSLS updated shareholders about business updates and quarterly results. in the results, the company stated that it successfully completed the merger with Obalon Therapeutics. In addition to this, it also completed a capital raise of roughly $46 million, while eliminating its debt overhang.
“As indicated by our preliminary results, the second quarter proved to be monumental for the Company. During this period, we completed our highly anticipated merger with Obalon Therapeutics, increased visibility in the financial markets by listing on the Nasdaq, and bolstered our diverse product portfolio with the launch of our online wellness hub, ReShape MarketPlace.”Bart Bandy, President, and CEO of ReShape Lifesciences
This is all big news for the company and helps to explain its over 40% gain in the past year. In the U.S. and abroad, weight loss is a major industry with only a handful of players that are capitalizing upon it. For this reason, RSLS could be poised to take advantage of the future of this market. Taking all of this into consideration, will RSLS stock be on your penny stocks watchlist this month?
Are Biotech Penny Stocks Worth Buying?
Finding the best biotech penny stocks to buy is all about understanding where to look. With so many different companies to choose from it can be difficult to pick just one or two for your watchlist.
However, with the right research at hand and a dedication to finding information, making a list of penny stocks to watch in the biotech sector can be easy. Considering all of this, are biotech penny stocks worth buying or not?